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Abstract: 
Purpose: We conducted a pilot study to assess the feasibility and the potential implications of 
detecting TERT promoter (TERTp)-mutant cell-free tumor-derived DNA (tDNA) in the 
cerebrospinal fluid (CSF) and plasma of glioblastoma patients. 
Experimental Design: Matched CSF and plasma samples were collected in 60 patients with 
glial tumors. The CSF collection was obtained during surgery, before any surgical manipulation 
of the tumor. The extracted tDNA and corresponding tumor DNA samples were analyzed for 
TERTp and isocitrate dehydrogenase (IDH) hotspot mutations. In addition, the variant allele 
frequency (VAF) of TERTp mutation in the CSF-tDNA was correlated with tumor features and 
patients’ outcome. 
Results: Thirty-eight patients had TERTp-mutant/IDH wild-type glioblastomas. The matched 
TERTp mutation in the CSF-tDNA was successfully detected with 100% specificity and 92.1% 
sensitivity (n=35/38). In contrast, the sensitivity in the plasma-tDNA was far lower (n=3/38, 
7.9%). We concordantly observed a longer overall survival of patients with low VAF in the CSF-
tDNA when compared to patients with high VAF, irrespective of using the lower quartile VAF 
(11.45%) [14.0 mo. (95%CI 10.3-17.6) vs. 8.6 mo. (95%CI 4.1-13.2), p=0.035], the lower third 
VAF (13%) [15.4 mo. (95%CI 11.6-19.2) vs. 8.3 mo. (95%CI 2.3-14.4), p=0.008] or the median 
VAF (20.3%) [14.0 mo. (95%CI 9.2-18.7) vs. 8.6 mo. (95%CI 7.5-9.8), p=0.062] to dichotomize 
the patients. 
Conclusions: This pilot study highlights the value of CSF-tDNA for an accurate and reliable 
detection of TERTp mutations. Furthermore, our findings suggest that high TERTp mutation 
VAF levels in the CSF-tDNA may represent a suitable predictor of poor survival in glioblastoma 
patients. Further studies are needed to complement the findings of our exploratory analysis. 
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Statement of translational relevance 
A clinical need exists to develop sensitive and specific biomarkers for glioblastoma diagnosis 
and recurrence detection. Recent studies have reported highly recurrent mutations in the TERT 
promoter region in > 90% of glioblastomas. These mutations have been further shown to be 
clonal and to confer a dismal prognosis. Consequently, if TERTp mutations could be detected in 
the CSF or plasma, this alteration could serve as a sensitive biomarker for glioblastomas. In this 
pilot study, we have established a clinical assay to detect TERTp mutations in the CSF-tDNA in 
patients with TERTp-mutant/IDH wild-type glioblastomas with 100% sensitivity and 92.1% 
specificity. In addition, we show an independent association between the TERTp mutation 
variant allele fraction (VAF) in the CSF-tDNA and patients’ survival. Although of exploratory 
nature, our results suggest that TERTp mutation detection in the CSF-tDNA has the potential to 
be a sensitive diagnostic tool in the management of glioblastoma patients. 
Introduction: 
Our knowledge about molecular markers in gliomas has undergone a rapid evolution in the last 
few years. Subsequently, a new generation of biomarkers has become available with the 
discovery of the genetic alterations that are responsible for the initiation and progression of 
gliomas, including telomerase reverse transcriptase promoter (TERTp) and isocitrate 
dehydrogenase (IDH) mutations (1-5). 
TERTp mutations are one of the most common recurrent alterations (90%) in glioblastomas and 
were found to be clonal in both pre-treatment and post-treatment autopsy samples in most 
glioblastoma patients (6). Moreover, the presence of somatic TERTp mutations in glioblastomas 
confers a dismal prognosis (7,8). In contrast, only a minority of glioblastomas harbor IDH1 
mutations (5%) and were shown to represent a distinct subset with favorable outcomes (5,8). 
on May 2, 2019. © 2018 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 25, 2018; DOI: 10.1158/1078-0432.CCR-17-3717 
6 
Consequently, screening for TERTp and IDH1 mutations in glioblastoma patients is of clinical 
value in survival prediction.  
The tDNA contains identical genetic alterations to those detected in the primary tumor itself. 
Therefore, in numerous cancer types, circulating tDNA detection in the plasma has been shown 
to be a reliable tool for monitoring, diagnosis and prognostication (9-15). However, in primary 
and metastatic brain tumors, the levels of tDNA in the plasma are low and inconsistently 
detectable (12). Moreover, tDNA assessment has not yet been established in the clinical 
management of glioma patients and, to date, no study has systematically evaluated the clinical 
value of TERTp mutation detection in the plasma or CSF in a large cohort of IDH wild-type 
glioblastomas.  
With this in mind, we conducted a pilot prospective study to assess TERTp and IDH hotspot 
mutations in the CSF-tDNA and plasma-tDNA, collected during surgery. We exclusively 
evaluated data from patients with TERTp-mutant/IDH wild-type glioblastomas to reduce 
potential confounders. A further intention of our study is to explore a putative association 
between the burden of the TERTp mutation in the tDNA and patients’ outcome. 
Patients and Methods 
Study population and intraoperative sample collection 
Specimens were collected between July 2015 and September 2017 at the time of surgery from 
60 patients who underwent tumor resection of newly diagnosed intracranial tumors that were 
suspicious for a diffuse glioma. Upon general anesthesia, 8-10 ml whole blood were withdrawn 
from every patient and 2-4 ml CSF were collected during surgery from the tumor site. The CSF 
collection was performed directly after opening the dura (durotomy), before any surgical 
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manipulation of the tumor, predominantly through dissection of the convexity subarachnoid 
space. 
Blood and CSF samples were collected in specific tubes preserving the tDNA (cell free DNA-
BCT Tubes, Streck, Omaha, NE, USA). For separation of plasma, blood samples were 
centrifuged at 300 g for 20 min. Without disturbing the buffy coat, the plasma layer (supernatant) 
was carefully removed and transferred into a new 2 mL low-bind tube. We also collected the 
pelleted material to assess TERTp mutations in the cellular fraction of the CSF. To completely 
remove residual cells, both plasma and CSF samples were subsequently centrifuged at 5000 g 
for 10 min and stored at -20 °C until downstream processing.  
The present study was conducted according to the guidelines of the Declaration of Helsinki and 
has been approved by the local Ethics Committee of the Medical Faculty Carl Gustav Carus 
Dresden. All samples (CSF, blood and tumor tissue) were collected with written consent from 
the patients.  
Tumor tissue preparation and DNA extraction 
Tumor tissues were taken intraoperatively and were snap frozen at -80°C. Frozen tumor tissue 
was sectioned using a cryotome (Cryostat Jung CM 1800; Leica). To assure a tumor cell 
content of at least 80% for nucleic acid extraction, control slides stained with hematoxylin and 
eosin were examined by the local neuropathologist (M.M.). For DNA isolation, the QIAmp DNA 
Mini Kit (Qiagen, Hilden, Germany) was used.  
Extraction and quantification of cell-free DNA 
Cell-free DNA was extracted using the Quick-ctDNA Serum & Plasma Kit (Zymo Research, 
Orange, CA, USA) according to manufacturer’s protocols. Briefly, stored CSF and plasma 
samples were thawed at room temperature. Samples were incubated with proteinase K in 
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digestion buffer for 30 min at 55 °C in a water bath. After mixing with DNA binding buffer, 
samples were loaded into the Zymo-Spin III-S column assembly and centrifuged at 1.000 g for 2 
min. After washing and centrifugation (10.000 g; 30 sec), ctDNA was eluted in 35 μL TE-buffer 
(10 mM Tris, 0.1 mM EDTA, pH8). The DNA concentration was measured by quantitative Real-
Time PCR on an ABI7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) 
using primers and probes for the ß-globin locus. 
PCR amplification of the TERT-promoter region 
A nested PCR procedure was used to amplify the proximal TERT promoter covering nucleotide 
numbers C228T and C250T (chr5:1295228 C>T and 1295250 C>T; hg19) from plasma-tDNA 
samples as well as genomic cellular DNA from the tumor specimens. Primer sequences for the 
first PCR were 5′-GGCCGATTCGACCTCTCT-3′ (TERT-p-f) and 5′-
AGCACCTCGCGGTAGTGG-3′ (TERT-p-r), amplifying a 489bp fragment of the TERT promoter 
region. PCR was carried out using the Qiagen Multiplex PCR Kit (Qiagen, Hilden, Germany) in a 
50-μl solution, consisting of a Multiplex PCR Mix (1x), Q-solution (1x), 0.2 µM each TERT-p-f/r
and 5 ng of template DNA. PCR was performed on a GeneAmp PCR System 9700 (Applied 
Biosystems) with an initial denaturation step at 95 °C for 15 min, followed by 25 cycles of 
denaturation at 94 °C for 1 min, annealing/extension at 59 °C for 3 min and a final extension at 
60 °C for 10 min. 
Second-round (nested) PCR was accomplished using the Q5 High-Fidelity Master Mix (New 
England Biolabs, Beverly, MA, USA) and fusion-primers 5′- AGTGGATTCGCGGGCACAGA -3′ 
(forward) and 5′- CAGCGCTGCCTGAAACTC -3′ (reverse) to attach the Ion A and truncated P1 
(trP1) adapter sequences to the amplicons, resulting in a 303 bp PCR product. Final reaction 
mixture (50 µl) consisted of Q5 Buffer (1x), 1 u Q5 polymerases, 0.5 µM of each fusion-primer, 
0.2 mM dNTPs and 1 µl of first-round PCR product as template. The PCR consisted of: 30 sec. 
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at 98°C; and 30 cycles of 5 sec. at 98°C, 10 sec. at 68°C and 20 sec. at 72°C with a final 
extension at 72°C for 2 min.  
Library preparation, sequencing and data analysis 
The PCR reactions were purified using a two‐round purification process with Agencourt AMPure 
XP Reagent (Beckman Coulter, Krefeld, Germany) and eluted in 30-50 μl ddH2O. The barcoded 
PCR products were quantified with a Qubit 2.0 fluorometer (Life Technologies) using the Qubit 
dsDNA HS Assay (Life Technologies) and sequenced uni-directionally on an Ion Torrent PGM 
NGS system (Life Technologies, Grand Island, NY, USA), according to the manufacturer's 
protocols(16). 
Briefly, the pooled library was clonally amplified on Ion Sphere™ Particles (ISPs) in an emulsion 
PCR using the Ion PGM Hi-Q OT2 Kit (Life Technologies). Enrichment of positive Ion Spheres 
(ISPs) was achieved using DynaBeadsMyOne streptavidin C1 beads (Life Technologies). 
Quantification of recovered particles was performed using a Qubit 2.0 fluorometer (Life 
Technologies) and an Ion Sphere quality control kit (Life Technologies). Ion Torrent chips (316 
Chip kit v2; Life Technologies) were prepared and loaded according to the manufacturer's 
protocol. PGM sequencing (Ion PGM Hi-Q Sequencing Kit; Life Technologies) was done with 
500 flows, 18 µs water and argon gas to drive fluidics. Data were analyzed with Torrent Suite 
3.0 or higher with alignment against Hg19 and the Variant Caller plugin. The quantitative 
accuracy was documented using dilutions of TERTp-mutant cell line Calu-1 (DSML, 
Brauschweig, Germany) in normal DNA (Suppl. Figure S1). In addition, we determined the 
diagnostic sensitivity and specificity of our assay by analyzing DNA extracted from the CSF 
cellular components in patients with non-tumor-related hydrocephalus during shunt implantation 
(n=6). 
Digital PCR 
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Digital droplet PCR (ddPCR) was performed on a Bio-Rad QX200 using the Bio-Rad TERT 
C228T_113 Assay (Assay ID dHsaEXD72405942). The detailed method is provided in the 
supporting information.    
IDH mutation detection in tumor tissue  
IDH1/2 mutation detection was performed in the tumor tissue based on conventional Sanger 
sequencing, using established primer sets, as published elsewhere by our group (17). 
MGMT promoter methylation assessment in tumor tissue  
MGMT promoter methylation status was determined by the methylation-specific polymerase 
chain reaction (MsPCR), as described by Esteller et al.(18).  
Radiological evaluation and volumetric measurements  
All patients in the study received a pre- and postop. MRI (day one after surgery) with T1, T1 
post-contrast, T2 and FLAIR sequences. Radiologic progression was determined using the 
criteria for Response Assessment in Neuro-Oncology (RANO)(19). Additionally, the 
preoperative T1-weighted post-contrast MR scans were used to measure the enhancing tumor 
size and obtain volumetric measurements. A combination of manual segmentation using the 
ITK-SNAP software(20) and intensity filtering based on individually adjusted thresholds was 
used to select the enhancing tumor tissue with and without the necrotic tumor portion. 
To investigate correlations between the successful detection of TERTp-mutant tDNA and tumor 
location, we used a previously described MRI-based classification of gliomas (21) to assess the 
spatial relationship of the tumor with the subventricular zone (SVZ) and the cortex as follows:  
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Group 1 Tumor contacting SVZ and infiltrating cortex 
Group 2 Tumor contacting SVZ but not involving cortex 
Group 3 Tumor not contacting SVZ but involving cortex 
Group 4 Tumor neither contacting SVZ nor infiltrating cortex 
Statistical analysis 
The Kaplan-Meier technique was used to estimate progression free survival (PFS) and overall 
survival (OS) and tested for significance by the log-rank test. PFS was calculated from the day 
of surgery until MRI-confirmed tumor progression or end of follow-up. OS was defined as the 
interval from the day of first surgery until death or the end of follow-up. The Mann-Whitney U 
and Fisher’s exact tests were used to test for association of clinical variables and CSF-tDNA, 
whereas the Spearman test was used to correlate coefficients among outcomes of the contrast-
enhancing tumor volume with the abundance of the mutant CSF-tDNA. Multivariate Cox 
regression models were applied to assess the impact of CSF-tDNA on patient's outcome. All p 
values are two-sided, and all analyses were conducted using the SPSS software package 
(Version 21.0 SPSS Inc., Chicago, IL, USA). 
Results: 
Patients’ characteristics  
Out of 60 patients who underwent surgery for an intracranial tumor, we identified 38 patients (24 
males and 14 females) with TERTp-mutant/IDH wild-type glioblastomas who were enrolled into 
our study (Figure 1). The median patient age at initial diagnosis was 67.6 years (range: 64.3 – 
71.4 years). Patient characteristics and tumor features are shown in Table 1. 
Gross total resection of the enhancing tumor – as evaluated by early postoperative MRI -- was 
achieved in 20 patients, while 18 patients underwent a subtotal resection. Radiation therapy 
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was applied in all cases, and 31 patients were treated concomitantly with temozolomide. 
Temozolomide therapy was prematurely discontinued in seven patients, due to disease 
progression and in two patients because of hematologic toxicities.  
Our study had a median follow-up of 12.36 months (4.25 - 33.0 months). The median PFS of 
patients with a newly-diagnosed GBM was 5.7 months (4.2 – 7.2 months) and the median OS 
was 9.9 months (6.7 – 13.2 months). 29 patients (78.3%) passed away during the time of follow-
up. The last update of progression status was performed in April 2018. 
TERTp mutation detection 
The median coverage for tumor tissue samples was 48170 reads (range 42716–60268 reads), 
for CSF it was 48890 reads (range 8680–198576 reads) and for plasma samples it was 49700 
reads (range 6647–107900 reads). Using this approach, we could detect TERTp mutations in 
CSF-tDNA at allelic frequencies as low as 0.4% for C228T and 0.2% for C250T. The turnaround 
time from processing the CSF/plasma sample to final mutation data report was 3-5 days.  
In the tumor tissue, the detected TERTp hotspot mutations were located at 146 bp (referred to 
as C250T, n=7) and in 31 cases at 124 bp (referred to as C228T) upstream of the translation 
start of the TERT promoter. In the matched CSF-tDNA, the TERTp mutation was successfully 
detected in 35 out of 38 patients (92.1%) (Table 1).  
Remarkably, in four IDH-mutant/TERTp-mutant gliomas (oligodendrogliomas), we detected only 
one TERTp mutation in the CSF-tDNA (Supplementary Table 1). In contrast, no TERTp 
mutations were detectable in the CSF-tDNA of any of the patients with an IDH-mutant/TERTp 
wild-type glioma (n =7) or an IDH wild-type/TERTp wild-type glioma (n=5) or in patients with 
brain metastases (n=6). Additional sequencing of CSF cell-free DNA from six patients with a 
non-tumor-related hydrocephalus revealed no TERTp mutations. Taken together, these results 
show a specificity of 100% and a sensitivity of 92.1% (n= 35/38) in determining the TERTp 
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mutations in the CSF of TERTp-mutant glioblastoma patients. Repeated analyses of a subgroup 
of samples (n= 15) from the CSF-tDNA indicated a high reproducibility of our results, with a 
median standard deviation from mean of 7.6% (range: 1.3%-34.4%).  
Moreover, to validate our results, ddPCR was performed in duplicates of five TERTp-mutant and 
four TERTp wild-type samples. The ddPCR showed concordant results with those determined 
by the Ion Torrent system in all 9 cases. However, our study has a limited power to sufficiently 
address the question which method is superior in terms of TERTp mutation detection in the 
CSF-tDNA. 
The sensitivity of TERTp mutation assessment in the plasma-tDNA was far lower (7.9%, n=3) 
than in the CSF (Fisher exact test p< 0.0001). All three patients with detectable TERTp mutation 
in plasma-tDNA had large glioblastomas with tumor infiltration of the choroid plexus and 
encasement of one major cerebral artery.   
 
Association between CSF-ctDNA detection and tumor volume and location  
To investigate whether the tumor size might affect the TERTp mutation detection in the CSF, we 
performed volumetric tumor measurements. The median gross tumor volume was 59.2 cm3 
(range 1.8 -177.2 cm3) and the median contrast-enhancing tumor volume was 45.5 cm3 (range: 
1.5 – 105.33 cm3).  
Among the 29 newly-diagnosed GBM cases with detectable TERTp mutations in the CSF and 
an available follow-up, we observed a statistically significant linear correlation between the 
VAFs and either the gross tumor volume (Spearman-Rho = 0.55; p=0.002) and the (Gadolinium-
) contrast-enhanced tumor volume (Spearman-Rho = 0.54; p= 0.003) (Figure 2).  
In terms of anatomical location, all but one tumor was adjacent to the CSF space through 
infiltration of the subventricular zone and/or the cortical subarachnoidal space (groups 1-3) 
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(Figure 3 and Table 1). Interestingly, the only patient with a tumor that was entirely 
encapsulated by the brain parenchyma (Group 4, Table 1) was one of the three patients with 
non-detectable TERTp mutations in the CSF (Supplementary Figure S2).  
Notably, we did not observe a significant association between the TERTp mutation VAF in the 
CSF-tDNA and patients’ age, sex or performance status. 
Association between TERTp mutation VAF in CSF-tDNA and patients’ outcome 
To explore a potential role of the TERTp mutation VAF in the CSF-tDNA in predicting patients’ 
survival, Kaplan-Meier curves were generated and analyzed based on the TERTp mutation 
VAFs in the CSF-tDNA. It was concordantly observed, that patients with low VAF in the CSF-
tDNA had a longer OS when compared to patients with high VAF, irrespective of using the lower 
quartile VAF of 11.45%, the lower third VAF of 13% or the median VAF of 20.3% to dichotomize 
the patients (p = 0.035, p = 0.008 and p = 0.062, respectively) (Figure 4).  
To substantiate our findings, a multivariate analysis was performed including all first-diagnosed 
glioblastoma patients with detectable TERTp-mutant CSF-tDNA and available follow-up (n=29). 
The TERTp mutation VAF with a cut off of 13% was found to be an independent prognostic 
factor for OS (p= 0.001, HR= 16.02, 95% CI: 3.15 – 28.43) (Table 2). By exploring an 
interaction between the tumor volume and a TERTp mutation VAF cut off of 13% in the CSF-
tDNA as one factor in the multi-variate analysis, the HR was 2.07, 95% CI 1.33-3.22, p = 0.001. 
All other included clinical parameters such as age, extent of resection, MGMT promoter status 
were not independent prognostic factors in our cohort, although it is possible that there are other 
clinical variables which may account for the differences in outcome. 
Postoperative TERTp mutation detection in the CSF-tDNA 
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To examine a potential application of CSF-tDNA as a marker for postoperative residual disease, 
CSF was collected in five patients who had intraoperatively detectable TERTp mutation in the 
CSF-tDNA and underwent a lumbar drainage placement to treat a postoperative CSF leakage. 
Interestingly, we saw a dramatic decrease of VAF levels (p= 0.043, Wilcoxon-signed rank test) 
(Supplementary Figure S3). However, although GTR was achieved in all five patients, TERTp 
mutation in the CSF-tDNA was postoperatively detectable in only two cases. Remarkably, 
persistent postoperative TERTp mutation detection in the lumbar spine CSF was associated 
with a decreased PFS of both patients (5.1 months), compared with the three patients with non-
detectable mutation who had a longer PFS (median 11.9 months, 95% CI 8.3 – 15.5 months). 
However, given the small group of patients, our study was likely underpowered to make any 
significant conclusions about differences in survival outcomes.       
Discussion: 
Detection of circulating tumor material has been shown to be of clinical value for diagnosis, 
prediction of response to treatment, and prognosis in cancer patients (10,11,14,15,22). In this 
pilot study, we demonstrate that TERTp mutation detection in intraoperatively collected CSF is 
feasible with a very high sensitivity and specificity in glioblastoma with spatial relationship to a 
CSF reservoir in the brain, consistent with the findings from previous studies (23,24). 
Remarkably, we observed a significant association between the VAF of the TERTp mutation in 
the CSF-tDNA and the outcome of glioblastoma patients in our cohort. Using different cutoffs, 
our data consistently showed that an increasing burden of TERTp-mutant alleles in the CSF-
tDNA was associated with unfavorable outcomes, suggesting a high reliability of the TERTp 
mutation VAF levels in the CSF-tDNA as an outcome prediction tool in glioblastoma patients. 
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Furthermore, we found a lower sensitivity of TERTp mutation detection in a distinct subset of 
TERTp-mutant/IDH-mutant gliomas (oligodendrogliomas), confirming the findings of a recent 
study that reported on the inability to detect molecular alterations in the CSF-tDNA in some low-
grade gliomas (24). This may be explained by the fact that glioblastomas have more severe 
blood-brain barrier integrity disruption compared to oligodendrogliomas, which is presumably 
associated with larger quantities of tDNA shedding into the CSF.  
A further potential application for CSF-tDNA is its use as a marker for postoperative residual 
disease. Presently, predicting the disease-free status of patients is predominantly based on 
clinical and radiological criteria. Interestingly, fluctuations in circulating tDNA levels have been 
shown to occur prior to changes seen in imaging studies (10). Moreover, it has been 
demonstrated that levels of circulating tDNA increase with disease progression and 
correspondingly decrease with response to therapy in solid tumors and glioblastomas 
(10,11,25,26). In the current study, we demonstrate an association between patients’ outcome 
and intra-/postoperative TERTp mutation CSF-tDNA levels in five cases. A significant 
postoperative reduction of the TERTp mutation VAF in the CSF-DNA when compared with the 
“baseline” intraoperative VAF level was associated with favorable survival outcomes. Although 
preliminary, this finding suggests that clearance of TERTp mutations in the CSF may indicate 
residual disease in glioblastoma patients and may be used for disease monitoring. However, 
this observation needs to be verified in a larger cohort of patients before any definitive 
conclusions can be made.  
In concordance with earlier studies, our assay to detect TERTp-mutant plasma-tDNA had a low 
sensitivity(12). Diaz et al. reported that mutant DNA fragments were found in high 
concentrations in the circulation of most patients with metastatic cancer – e.g. melanoma, 
breast or colon cancers -- and at lower concentrations in patients with localized cancers, as in 
gliomas or prostate cancer(13,27). Similarly, a recent study showed that levels of CSF-tDNA 
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were considered significantly enriched when compared to the corresponding plasma in 12 
individuals with primary or metastatic brain tumors(28). In order to improve this shortcoming, 
new technologies are needed. For instance, an innovative technique employed focused 
ultrasound to increase the release of brain tumor material into the bloodstream, essentially 
making blood a viable surrogate for tumor detection (29).  
Although we suggest that TERTp mutation detection in the CSF-tDNA has the potential to be 
developed as a diagnostic instrument in the management of glioblastoma patients, we 
acknowledge that our approach to collect CSF at the time of surgery was not intended as a 
preoperative diagnostic tool. From a clinical standpoint, the preoperative detection of TERTp 
mutation in the CSF-tDNA by lumbar puncture would be more readily accessible than by 
intraoperative surgery, notwithstanding the consideration of lumbar punctures as an invasive 
procedure. Consequently, the assessment of genomic alterations at several longitudinal time 
points as a “liquid biopsy” is a consequential approach to monitor tumor progression and to 
correlate with radiographic findings. Ultimately, this serial approach may avoid unnecessary 
surgical procedures and lead to better management of glioblastoma patients. Lastly, a recent 
study showed a very low congruence for same patient-paired prostate cancer samples between 
different laboratories(30), raising the question whether the results generated by our assay could 
be generalized to other laboratories or attained by using different assays. Therefore, to 
complement our study, confirmatory observational cohorts with more patients and further 
techniques are certainly needed to determine precise cutoffs of the TERTp mutation VAF that 
may be used to define patients at high-risk for rapid progression.   
In conclusion, our pilot study highlights the value of CSF-tDNA for an accurate and reliable 
detection of TERTp mutations in glioblastomas. Furthermore, our findings suggest that high 
TERTp mutation VAF levels in the CSF-tDNA may be a suitable predictor of poor survival in 
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glioblastoma patients. This would allow for a more precise risk stratification of patients for 
clinical trials. Further studies are needed to validate the findings of this exploratory analysis. 
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Figures legends: 
Figure1. Schematic representation of the inclusion flow used in this study. 
Figure 2. Linear regression between the VAFs and tumor volume among the 23 cases in which 
detectable TERTp mutation was found in the CSF-ctDNA. A statistically significant linear 
correlation between the VAFs and either the gross tumor volume (R2 = 0.36; p = 0.0017) and 
the (Gadolinium-) contrast-enhanced tumor volume (R2 = 0.40; p = 0.0008) was observed.  
Figure 3. The MRI-based classification of the tumor location in 38 patients with IDH wild-type/ 
TERTp-mutant glioblastomas to assess the spatial relationship with the ventricle system and 
cortex with an example of every group (SVZ: subventricular zone)  
Group 1 Tumor contacting SVZ and infiltrating cortex (52%) 
Group 2 Tumor contacting SVZ but not involving cortex (24%) 
Group 3 Tumor not contacting SVZ but involving cortex (21%) 
Group 4 Tumor neither contacting SVZ nor infiltrating cortex (3%) 
Figure 4: Kaplan-Meier estimates of overall survival. The detected TERTp mutation tDNA-VAF 
shows a significant prognostic value on patients’ survival. Patients with low VAF in the CSF-
tDNA have longer overall survival when compared to patients with high VAF, irrespective of 
using the lower quartile VAF (11.45%) [14.0 mo. (95%CI 10.3-17.6) vs. 8.6 mo. (95% CI 4.1-
13.2), p=0.035], the lower third VAF (13%) [15.4 mo. (95%CI 11.6-19.2) vs. 8.3 mo. (95% CI 
2.3-14.4), p=0.008] or the median VAF (20.3%) [14.0 mo. (95%CI 9.2-18.7) vs. 8.6 mo. (95% CI 
7.5-9.8), p=0.062], to dichotomize the patients. 
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Table 1
Patient ID Sex
Age at first 
surgery 
(years)
Histology Extent of resection
IDH  mution 
status/tumor 
tissue
MGMT 
promoter status
GBM_NCH01 male 66 GBM GTR wild-type unmethylated
GBM_NCH02 male 75 GBM STR wild-type unmethylated
GBM_NCH04 male 72 GBM STR wild-type methylated
GBM_NCH06 female 72 GBM STR wild-type unmethylated
GBM_NCH07 female 62 GBM STR wild-type methylated
GBM_NCH09 male 64 GBM GTR wild-type unmethylated
GBM_NCH10 male 66 GBM GTR wild-type unmethylated
GBM_NCH17 female 63 GBM GTR wild-type unmethylated
GBM_NCH08 male 62 GBM STR wild-type unmethylated
GBM_NCH11 male 79 GBM GTR wild-type unmethylated
GBM_NCH14 male 57 GBM STR wild-type unmethylated
GBM_NCH13 male 79 GBM STR wild-type unmethylated
GBM_NCH19 female 62 GBM STR wild-type methylated
GBM_NCH29 male 45 GBM GTR wild-type unmethylated
GBM_NCH30 female 67 GBM GTR wild-type unmethylated
GBM_NCH33 male 64 GBM GTR wild-type unmethylated
GBM_NCH38 female 72 GBM STR wild-type methylated
GBM_NCH39 male 76 GBM GTR wild-type unmethylated
GBM_NCH41 female 73 GBM GTR wild-type unmethylated
GBM_NCH46 male 82 GBM STR wild-type unmethylated
GBM_NCH49 male 75 GBM GTR wild-type methylated
GBM_NCH50 female 49 GBM STR wild-type methylated
GBM_NCH51 female 72 GBM GTR wild-type unmethylated
GBM_NCH55 male 61 GBM STR wild-type methylated
GBM_NCH58 female 78 GBM STR wild-type unmethylated
GBM_NCH68 male 53 GBM GTR wild-type methylated
GBM_NCH66 male 77 recurrent GBM STR wild-type methylated
GBM_NCH69 male 59 GBM GTR wild-type methylated
GBM_NCH70 female 52 recurrent GBM GTR wild-type methylated
GBM_NCH71 male 71 GBM GTR wild-type methylated
GBM_NCH72 male 67 GBM STR wild-type methylated
GBM_NCH74 female 82 GBM GTR wild-type methylated
GBM_NCH75 male 76 GBM STR wild-type unmethylated
GBM_NCH76 female 72 recurrent GBM STR wild-type unmethylated
GBM_NCH56 male 55 GBM STR wild-type unmethylated
GBM_NCH80 male 83 GBM GTR wild-type unmethylated
GBM_NCH83 male 65 GBM GTR wild-type not determined 
GBM_NCH53 female 64 recurrent GBM GTR wild-type unmethylated
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TERT p 
mutation 
/tumor 
Intraoperative 
TERT p mution 
detection/CSF 
Intraoperative
VAF/CSF [%]  
Postoperative 
TERT p mution 
detection/CSF 
Postoperative 
VAF/CSF [%]
TERT p mutation 
detection/plasma
C228T yes 20.91 yes 9.30 no
C250T no 0.00 not determined no
C250T yes 44.44 not determined no
C228T yes 60.90 not determined no
C250T yes 70.03 not determined yes
C228T yes 14.80 not determined no
C228T yes 11.45 not determined no
C228T yes 4.96 not determined no
C228T yes 16.41 not determined no
C228T yes 44.50 not determined no
C228T yes 12.76 not determined no
C228T yes 38.54 not determined no
C250T no 0.13 not determined no
C250T yes 2.93 not determined no
C228T yes 1.76 no 0.18 no
C228T yes 3.17 not determined no
C228T yes 51.95 not determined no
C228T yes 13.65 not determined no
C228T yes 20.35 not determined yes
C228T yes 33.60 not determined no
C228T yes 29.56 not determined no
C228T yes 41.07 not determined no
C228T yes 20.11 not determined yes
C228T yes 20.61 not determined no
C228T yes 20.93 not determined no
C228T yes 5.94 no 0.06 no
C228T yes 11.01 not determined no
C228T yes 53.84 no 0.69 no
C228T yes 11.01 not determined no
C228T yes 18.82 not determined no
C228T yes 20.11 not determined no
C228T yes 38.16 not determined no
C228T no 0.14 not determined no
C250T yes 0.91 not determined no
C228T yes 3.26 not determined no
C250T yes 4.47 not determined no
C228T yes 43.44 yes 2.92 no
C228T yes 19.34 not determined no
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VAF/plasma 
[%]
Gross tumor 
volume mm3
Volume of contrast 
enhanced tumor 
mm3 
Tumor 
location  Outcome
0.13 66833.53 53724.32 Group 2 deseased 
0.00 60772.75 32831.29 Group 1 deseased 
0.14 74224.45 60968.50 Group 2 deseased 
0.00 94466.03 61016.54 Group 1 deseased 
10.62 177251.17 105333.12 Group 1 deseased 
0.08 81252.39 61840.50 Group 1 deseased 
0.18 18712.70 14683.15 Group 3 deseased 
0.12 28823.60 20747.55 Group 3 deseased 
0.10 not determined not determined Group 1 deseased 
0.16 87319.59 62163.09 Group 1 deseased 
0.21 113304.20 76145.89 Group 1 deseased 
0.10 27968.99 22998.19 Group 1 deseased 
0.00 17148.51 12881.53 Group 4 deseased 
0.17 54706.97 40096.26 Group 1 deseased 
0.00 44666.13 32815.50 Group 3 alive
0.10 72386.63 43229.56 Group 1 deseased 
0.28 106570.64 101406.47 Group 1 deseased 
0.08 12296.64 6410.81 Group 3 deseased 
5.62 50192.29 42088.88 Group 2 deseased 
0.18 76629.59 48995.72 Group 1 deseased 
0.13 135806.45 93617.38 Group 2 deseased 
0.23 75922.40 56703.61 Group 2 deseased 
35.38 20767.32 15543.69 Group 2 deseased 
0.13 88345.95 54917.92 Group 3 deseased 
0.15 85023 59706.00 Group 1 deseased 
0.12 3616.69 3033.74 Group 3 alive
0.45 10459.59 9188.76 Group 1 deseased 
0.15 66185.46 47871.99 Group 1 alive
0.11 79877.23 48156.71 Group 1 alive
0.12 38323.30 17340.88 Group 2 deseased 
0.22 57268.27 24060.59 Group 3 alive
0.17 56731.03 14887.91 Group 1 alive
0.11 62396.41 60236.68 Group 1 deseased 
0.15 38811.85 16240.43 Group 1 deseased 
0.17 39343.98 24915.7 Group 2 deseased 
0.025 not determined not determined Group 1 alive -short follow-up
0.03 not determined not determined Group 3 alive -short follow-up
0.13 1875.9 1503.4 Group 2 lost from follow-up
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Table 2 
Hazard ratio (HR) 95% CI p-value
Age ≥ 65 years 0.49 0.18-1.32 0.16 
Gross tumor volume 1.44 0.55-3.77 0.45 
Contrast-enhanced tumor volume 0.51 0.11-2.26 0.37 
Complete resection of contrast-enhanced tumor 1.03 0.37-2.88 0.94 
MGMT promoter methylation status 0.31 0.12-1.01 0.87 
Variant allele frequency (VAF) of TERTp 
mutation in the CSF-tDNA (cutoff 13%) 
16.02 3.15–28.43 0.001 
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